Clinical Nutrition · Nov 2026
Effects of Fish Oil Intervention on Residual Risk of Cardiovascular Disease in Middle-Aged and Elderly People: A Randomized Controlled Trial
By Tang W, Quan C, Qin Y et al.
Background and Aims Residual cardiovascular disease(CVD) risk persists despite achieving standard preventive targets, including controlled low-density lipoprotein cholesterol (LDL-C), blood pressure, and blood glucose. While omega-3 polyunsaturated fatty acids (n-3 PUFAs) supplementation improves lipid metabolism in CVD patients, its impact on residual risk is unclear. This 12-week randomized controlled trial therefore examined the effects of different fish oil doses on residual CVD risk in middle-aged and elderly individuals. Methods A total of 240 subjects were included in this study and randomly allocated into four groups: a control group and three intervention groups receiving different doses (0.31 g/d, 0.62 g/d, 1.24 g/d) of long-chain n-3 polyunsaturated fatty acids (LCn-3PUFAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The primary endpoint was the relative change from baseline to 12 weeks in serum residual risk indicators, namely remnant lipoprotein cholesterol (RLP-C), apolipoprotein A-I (ApoA-I), apolipoprotein B (ApoB), lipoprotein(a) [Lp(a)], and high-sensitivity C-reactive protein (hs-CRP). Results Compared with the control group, RLP-C was significantly lowered at doses of 0.31 g/d, 0.62 g/d, and 1.24 g/d (all P < 0.05), and ApoA-I was significantly increased at the same doses (all P < 0.05).The residual risk indices triglyceride-glucose (TyG) index and atherogenic index of plasma (AIP) were also significantly lowered at 0.31 g/d, 0.62 g/d, and 1.24 g/d compared with the control group (all P < 0.05). Compared with baseline, the Castelli risk index I (CRI-I) was reduced in the 1.24 g/d group (P < 0.05), and the ApoB/ApoA-I ratio was lowered in the 0.31 g/d and 0.62 g/d groups (all P < 0.05). In contrast, fish oil had no significant effect on serum levels of ApoB, Lp(a), or hs-CRP (all P > 0.05). Conclusions These data suggest that fish oil containing the specific EPA+DHA formulation used in this study may favorably modify several indices linked to residual cardiovascular disease risk in middle-aged and elderly people, although further long-term trials are necessary to confirm clinical cardiovascular benefits. Trial registration number ChiCTR-IOR-17012053 (registered at http://www.chictr.org.cn , Chinese Clinical Trial Registry).